Alogliptin/Metformin Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 12.5mg+500mg / 12.5mg+850mg / 12.5mg+1000mg
Reference Brands: Kazano (USA), Vipdomet (EU)
Category:
Diabetes
Alogliptin/Metformin is an oral medication for type 2 diabetes mellitus. It combines alogliptin, a DPP-4 inhibitor, and metformin, a biguanide, to help control blood sugar levels. The combination improves insulin response and reduces liver glucose production. Taken twice daily with meals, it is used when diet, exercise, or single-drug therapy is insufficient.
Alogliptin/Metformin is available in Tablets
and strengths such as 12.5mg+500mg / 12.5mg+850mg / 12.5mg+1000mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alogliptin/Metformin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alogliptin/Metformin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alogliptin / Metformin Hydrochloride tablets are an oral antidiabetic combination used for the management of type 2 diabetes mellitus. This formulation combines alogliptin, a DPP-4 inhibitor that enhances incretin hormone activity to increase insulin release and decrease glucagon levels, with metformin, which reduces hepatic glucose production and improves insulin sensitivity. Together, they provide effective glycemic control by targeting multiple pathways involved in glucose regulation. These tablets are commonly prescribed when monotherapy is insufficient and are typically used alongside diet and exercise to achieve better long-term blood sugar management and reduce the risk of diabetes-related complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing